Cadenza Software was developed by Dr. George Diamond and employs Bayes' theorem to analyze and report results of various clinical descriptors and noninvasive tests relative to the diagnosis of coronary artery disease. The data indicates that Bayes' theorem and Cadenza is an accurate, clinically applicable means for quantifying the prevalence of angiographic coronary artery disease, the risk of multivessel disease, and the incidence of morbid coronary events in the year after testing.

Joseph Oliverio, President of Positron states, "Assessing pre-test probability of disease accurately will be an essential tool for diagnostic testing facilities applying for prior-authorization approval from insurance companies. The use of Cadenza at a Positron customer site in New York State was critical for establishing and sustaining reimbursement. Cadenza software is a very important component to expand the acceptance of cardiac PET as a first line test in coronary disease similar to that of the well established SPECT technology. We believe that we will position Cadenza software to be embraced and demanded by Positron users and insurance companies across the country. Cadenza is the leading software algorithm that ensures the use of clinical evidence based medical software in deciding which test to approve in order to maximize patient outcome benefit and minimize overall costs."

According to Dr. Diamond, the integration ensures that sophisticated technology for diagnostic data acquisition will be supported by similarly sophisticated technology for clinical interpretation and therapeutic decision-making.

About Positron:

Positron Corporation designs, manufactures, markets and supports advanced medical imaging devices utilizing positron emission tomography (PET) technology under the trade name POSICAM(TM) systems. POSICAM(TM) systems incorporate patented and proprietary software and technology for the diagnosis and treatment of patients in the areas of cardiology, oncology and neurology. Positron Corporation offers unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers. POSICAM(TM) systems are in use at leading medical facilities, including the Weatherhead PET center at the University of Texas Health Science Center in Houston, Texas; The Heart Center of Niagara in Niagara Falls, New York; Beth Israel Medical Center, New York; Emory Crawford Long Hospital Carlyle Fraser Heart Center in Atlanta, Georgia; and Nishidai Clinic (Diagnostic Imaging Center) in Tokyo, Japan. Additional information may be found at www.positron.com.

Forward Looking Statements:

Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The words "expect," "anticipate," "intend," "plan," "believe," "seek," "estimate," and similar expressions are intended to identify such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

For further information please contact Joseph Oliverio at Positron Corporation at (281) 492-7100.